Listening to the Tumour’s Echo: A Blood Test That Hints at What Treatment Will Work

There is a quiet revolution unfolding in cancer care — one carried not on the shoulders of scanners and surgical tools but in the stream of genetic material that all tumours spill into the bloodstream. In the careful choreography of treatment decisions, oncologists strive to match therapy to biology, yet for decades the most precise answers came only after weeks or months of waiting and observation. Now, a simple blood test is promising to cut through uncertainty and give both doctors and patients an earlier signpost: a way to see how well a treatment is likely to work even before it has had time to take root.

Researchers at the Institute of Cancer Research (ICR) in London have developed a liquid biopsy — a blood test that measures tiny fragments of tumour DNA, known as circulating tumour DNA (ctDNA) — to show how metastatic breast cancer responds to therapy. By analysing ctDNA levels at the start of therapy and again after one cycle (about four weeks), the team found that patients with lower or undetectable ctDNA had markedly better outcomes: their cancers stayed under control longer, and they were more likely to respond to the drugs they were given.

This approach moves beyond conventional imaging and tissue biopsy by offering a non‑invasive, real‑time window into how a cancer is behaving. For people facing the daunting landscape of breast cancer treatment — where targeted drugs, combination therapies, and chemotherapy all carry physical and emotional weight — the ability to know sooner whether a particular strategy is working could spare unnecessary side effects and open the door to alternatives more quickly.

In the study, called the plasmaMATCH trial, the test was evaluated in patients with advanced breast cancer, including those with hard‑to‑treat subtypes. Those whose ctDNA fell to undetectable levels early in treatment tended to have higher response rates and longer periods without disease progression compared to those whose ctDNA stayed elevated. This pattern held both when predicting response before therapy began and after a single treatment cycle.

The implications are profound: instead of waiting weeks or months to see whether a tumour shrinks on scans, clinicians could use a simple blood draw to guide decisions much sooner. Patients who do not show early ctDNA declines might be candidates for alternative therapies, combinations of drugs, or even clinical trials testing novel agents. Tailoring treatment in this way reflects a broader shift toward precision oncology — care that is customized to the biology of each individual’s disease rather than a one‑size‑fits‑all model.

Experts emphasise that this test is not yet standard practice everywhere, and larger studies are ongoing to confirm whether acting on ctDNA results — such as switching therapies earlier — improves long‑term outcomes. But the early results suggest a future in which a simple blood test becomes an essential part of the breast cancer journey, empowering both clinicians and patients with clearer insight and less waiting.

In straight news terms, scientists at the Institute of Cancer Research have shown that measuring circulating tumour DNA with a liquid biopsy may help predict how well breast cancer patients respond to treatment, potentially allowing more timely and personalised therapy choices.

AI Image Disclaimer: Images are AI‑generated and intended for representation, not real photographs.

Sources: The Guardian The Telegraph Supporting ctDNA research in breast cancer studies